<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="virus (HSV), and the potential use of PPVIs for urgent" exact="treatment" post="of infection by newly emerging or re-emerging viruses. enveloped"/>
 <result pre="and the potential use of PPVIs for urgent treatment of" exact="infection" post="by newly emerging or re-emerging viruses. enveloped virus envelope"/>
 <result pre="(Wang et al., 2017). Since the first antiviral drug for" exact="treatment" post="of HIV infection, zidovudine, was approved for clinical use"/>
 <result pre="so far. They are mainly applied to treat and prevent" exact="infection" post="of HIV, herpes simplex virus (HSV), influenza virus, hepatitis"/>
 <result pre="for further development as novel antiviral drugs for the urgent" exact="treatment" post="of infection by the highly pathogenic emerging and re-emerging"/>
 <result pre="development as novel antiviral drugs for the urgent treatment of" exact="infection" post="by the highly pathogenic emerging and re-emerging viruses. In"/>
 <result pre="the traditional antiviral drugs and the potential application for urgent" exact="treatment" post="of infection by newly emerging and re-emerging viruses. Protein-"/>
 <result pre="antiviral drugs and the potential application for urgent treatment of" exact="infection" post="by newly emerging and re-emerging viruses. Protein- and Peptide-Based"/>
 <result pre="with these drugs brought about synergism or strong synergism against" exact="infection" post="of both X4 and R5 HIV-1 strains (Xu et"/>
 <result pre="Indeed, in vitro studies indicated that sCD4 could inhibit HIV-1" exact="infection" post="with IC50 (half maximal inhibitory concentration) values between 40"/>
 <result pre="short, leading to viral relapse within a short time after" exact="treatment" post="(Kahn et al., 1990; Schooley et al., 1990). At"/>
 <result pre="could not effectively inhibit HIV-1 infection, but rather enhanced the" exact="infection" post="of some HIV-1 clinical isolates in host cells, including"/>
 <result pre="fusion and infection. Unlike sCD4, CD4-IgG2 could not enhance HIV-1" exact="infection" post="in CD4- CCR5+ cells. Like the broadly neutralizing antibodies"/>
 <result pre="log10 mean reductions in viral load for 4â€&quot;6 weeks after" exact="treatment" post="were mediated by CD4-IgG2 (Jacobson et al., 2004). However,"/>
 <result pre="et al., 2004). However, the concern about the enhancement of" exact="infection" post="of some HIV-1 strains caused by sCD4- or CD4-containing"/>
 <result pre="gp120 with an IC50 of 40 Î¼M and suppressed the" exact="infection" post="of HIV-1 X4 and R5 strains with IC50s ranging"/>
 <result pre="stability, solubility and gp120-binding affinity, designated mD1.1 and mD1.2, through" exact="screening" post="a large D1 mutant library and found that both"/>
 <result pre="bispecific multivalent fusion proteins, 2Dm2m and 4Dm2m, which could inhibit" exact="infection" post="by all HIV-1 strains tested, including 41 HIV-1 isolates"/>
 <result pre="promising to be further developed into new anti-HIV drugs for" exact="treatment" post="and prevention of HIV infection. By screening phage display"/>
 <result pre="anti-HIV drugs for treatment and prevention of HIV infection. By" exact="screening" post="phage display libraries of random 12-mer peptides, Ferrer and"/>
 <result pre="development of specific HIV-1 inactivators with improved antiviral activity for" exact="treatment" post="and prevention of HIV-1 infection. The CD4bs on gp120"/>
 <result pre="negative-sense, single-stranded RNA genomes (Palese and Shaw, 2007). Influenza virus" exact="infection" post="can lead to a high fever, cough, headache, sore"/>
 <result pre="by Japanese and United States FDA and proved effective against" exact="infection" post="by influenza virus strains resistant to current anti-influenza drugs"/>
 <result pre="al., 2020). Also, these drugs mentioned above must inhibit viral" exact="infection" post="in the presence of target cells, instead of inactivating"/>
 <result pre="has good potential for further development into a first-line antiviral" exact="treatment" post="during influenza outbreaks. Using a computer-aided strategy based on"/>
 <result pre="et al., 2012; Yang et al., 2013) (Figure 3C). Through" exact="screening" post="a phage-displayed random peptide library, Matsubara et al. (2010)"/>
 <result pre="bind the RBSs in H1 and H3 HAs and inhibit" exact="infection" post="by the A/Puerto Rico/8/34 (H1N1) and A/Aichi/2/68 (H3N2) strains"/>
 <result pre="of 7-mer sialic acid-mimic peptides (Matsubara et al., 2016) by" exact="screening" post="another phage-displayed random peptide library. They found that these"/>
 <result pre="indicated that one of these peptides, C18-LVRPLAL, could strongly inhibit" exact="infection" post="by the A/Aichi/2/68 (H3N2) strain with an IC50 value"/>
 <result pre="genome, are enveloped viruses transmitted by hematophagous mosquito vectors. Flavivirus" exact="infection" post="may cause neurological, viscerotrophic or hemorrhagic diseases (Slon Campos"/>
 <result pre="(WNV), and so on (Kuno et al., 1998). Zika virus" exact="infection" post="usually causes mild symptoms, such as rash, fever, headache,"/>
 <result pre="some cases, such as Guillain-BarrÃ© syndrome, meningo-encephalitis and myelitis. ZIKV" exact="infection" post="of pregnant women may cause microcephaly in their fetuses"/>
 <result pre="chaperone, plays a vital role during the process of viral" exact="infection" post="and maturation (Li et al., 2008). As shown in"/>
 <result pre="(Li et al., 2008). As shown in Figure 4B, DENV" exact="infection" post="is initiated by binding of domain III of E"/>
 <result pre="region (residues 692â€&quot;724) with amphipathicity and membrane-binding ability, could inhibit" exact="infection" post="of all four serotypes of DENV with IC50 values"/>
 <result pre="protein (residues 421â€&quot;453), and similarly Z2 was shown to inhibit" exact="infection" post="by different strains of ZIKV and other flaviviruses, including"/>
 <result pre="II beta sheet connection (residues 41â€&quot;60), respectively, could inhibit DENV-2" exact="infection" post="with IC50 values of 8 and 7 Î¼M, respectively."/>
 <result pre="that the dipeptide Glu-Phe (EF for short) could inhibit the" exact="infection" post="of all four DENV serotypes, but it was the"/>
 <result pre="They found that peptides DET2 and DET4 could inhibit DENV-2" exact="infection" post="with IC50 values of 500 and 35 Î¼M, respectively."/>
 <result pre="ectodomain of M protein, and found that it could inhibit" exact="infection" post="of four serotypes of DENV with IC50 values ranging"/>
 <result pre="oral and genital ulcers to devastating encephalitis. Following the initial" exact="infection" post="at a peripheral site, it will establish a lifetime"/>
 <result pre="far, three categories of drugs have got approval for the" exact="treatment" post="of HSV infection, including (1) the nucleoside analogs such"/>
 <result pre="higher production cost, PPVIs are generally more expensive for long-term" exact="treatment" post="of chronic viral infection. Lentiviral vector-based gene therapy to"/>
 <result pre="encoding secreted anti-HIV proteins including sCD4, which could prohibit the" exact="infection" post="of both gene-modified and unmodified cells. They further investigated"/>
 <result pre="mentioned above may not be the problems for the urgent" exact="treatment" post="of the highly pathogenic emerging and re-emerging virus infections,"/>
 <result pre="believe that more and more PPVIs will be developed for" exact="treatment" post="and prevention of viral infections, particularly useful for combating"/>
 <result pre="types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus" exact="infection" post="in ferrets.J. Virol.8410366â€&quot;10374. 10.1128/JVI.01035-1020686020 BrightR. A.ShayD. K.ShuB.CoxN. J.KlimovA. I."/>
 <result pre="herpes simplex virus type 2 are capable of blocking herpetic" exact="infection" post="in vitro.Intervirology59235â€&quot;242. 10.1159/00046413428329739 ChaikenI.RashadA. A. (2015). Peptide triazole inactivators"/>
 <result pre="calcium release and promote viral entry: novel candidate target for" exact="treatment" post="and suppression.FASEB J.272584â€&quot;2599. 10.1096/fj.12-22028523507869 ChewM. F.PohK. S.PohC. L. (2017)."/>
 <result pre="T.TruongH. K.VoM. H.SmithG. J.NguyenV. C.et al. (2005). Oseltamivir resistance during" exact="treatment" post="of influenza A (H5N1) infection.N. Engl. J. Med.3532667â€&quot;2672. 10.1056/NEJMoa05451216371632"/>
 <result pre="cells.Gene Ther.21175â€&quot;187. 10.1038/gt.2013.7024305417 FalkenhagenA.SinghJ.AsadS.LeontyevD.ReadS.Zuniga-PfluckerJ. C.et al. (2017). Control of HIV" exact="infection" post="in vivo using gene therapy with a secreted entry"/>
 <result pre="R.PrinciottoA.et al. (2009). Soluble CD4 and CD4-mimetic compounds inhibit HIV-1" exact="infection" post="by induction of a short-lived activated state.PLoS Pathog.5:e100036010.1371/journal.ppat.1000360 HalsteadS."/>
 <result pre="B. (2007). Dengue.Lancet3701644â€&quot;1652. 10.1016/S0140-6736(07)61687-017993365 HanY.MespledeT. (2018). Investigational drugs for the" exact="treatment" post="of Zika virus infection: a preclinical and clinical update.Expert"/>
 <result pre="inhibition by a peptide.Nature365:11310.1038/365113a0 JiangS.LinK.StrickN.NeurathA. R. (1993b). Inhibition of HIV-1" exact="infection" post="by a fusion domain binding peptide from the HIV-1"/>
 <result pre="al. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV" exact="infection" post="in North and South America.N. Engl. J. Med.3482175â€&quot;2185. 10.1056/NEJMoa03502612637625"/>
 <result pre="Immunol. Res.2019:649173810.1155/2019/6491738 NgK. E. (2019). Xofluza (Baloxavir Marboxil) for the" exact="treatment" post="of acute uncomplicated influenza.P T449â€&quot;11.30675086 NicolaA. V. (2016). Herpesvirus"/>
 <result pre="PerezE. E.RileyJ. L.CarrollR. G.von LaerD.JuneC. H. (2005). Suppression of HIV-1" exact="infection" post="in primary CD4 T cells transduced with a self-inactivating"/>
 <result pre="(2020). Detection of variants with reduced baloxavir marboxil susceptibility after" exact="treatment" post="of children with influenza A during the 2018/2019 influenza"/>
 <result pre="K.QianX.et al. (2016). Identification of small-molecule inhibitors of Zika virus" exact="infection" post="and induced neural cell death via a drug repurposing"/>
 <result pre="Q.ZouP.WangQ.DaiY.YuF.et al. (2017). A peptide-based viral inactivator inhibits Zika virus" exact="infection" post="in pregnant mice and fetuses.Nat. Commun.8:1567210.1038/ncomms15672 ZamanR.IslamR. A.IbnatN.OthmanI.ZainiA.LeeC. Y.et"/>
</results>
